Skip to main content

Peer Review reports

From: One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry study

Original Submission
15 Aug 2023 Submitted Original manuscript
25 Aug 2023 Reviewed Reviewer Report
26 Sep 2023 Reviewed Reviewer Report
14 Oct 2023 Author responded Author comments - Michel Lanteri-Minet
Resubmission - Version 2
14 Oct 2023 Submitted Manuscript version 2
16 Oct 2023 Editorially accepted
8 Nov 2023 Article published 10.1186/s10194-023-01680-4

You can find further information about peer review here.

Back to article page